# US 2005/0233403 A1 · Human adipocyte cell populations and methods for identifying modulators of same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233403 A1
- Document ID: US20050233403A1
- Status: Published application
- Kind: A1
- Application number: 10/513,066
- Filed: 2003-05-01
- Published: 2005-10-20
- Earliest claimed: 2002-05-01
- Assignees: AdipoGenix, Inc.
- Inventors: Michael Stevenson; James Kirkland
- Web page: https://patentgrep.com/patent/US20050233403A1

## CPC

- G01N 33/5073: {Stem cells}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5014: {for testing toxicity}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/39: Steroid hormones
- C12N 2501/395: Thyroid hormones
- C12N 2503/02: Drug screening
- C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention features methods of obtaining high-yield, essentially pure human predipocyte cultures. Cultures obtained according to the instant methodology are also featured as are methods of identifying adipogenic modulatory agents, e.g., high-throughput screening assays.

## Claims

### Claim 1

A method for identifying a fat modulatory compound, comprising:
(a) obtaining a high-yield, essentially pure human preadipocyte population;
(b) culturing said preadipocyte population under conditions sufficient to induce differentiation;
(c) contacting said population with a test compound at least 1-3 days following initial culture in the differentiation medium;
(d) maintaining said population in the presence of said test compound; and
(e) assaying the population for fatty-acid uptake or accumulation, a detectable fluctuation in which indicates that the test compound is a fat modulatory compound.

### Claim 2

A method for identifying a fat modulatory compound, comprising:
(a) obtaining a high-yield, essentially pure human preadipocyte population;
(b) culturing said preadipocyte population under conditions sufficient to induce differentiation;
(c) contacting said population with a test compound at least 6-10 days following initial culture in the differentiation medium;
(d) maintaining said population in the presence of said test compound; and
(e) assaying the population for fatty-acid uptake or accumulation, a detectable fluctuation in which indicates that the test compound is a fat modulatory compound.

### Claim 3

A method for identifying a potential weight loss or anti-obesity agent, comprising:
(a) obtaining a high-yield, essentially pure human preadipocyte population;
(b) culturing said preadipocyte population under conditions sufficient to induce differentiation;
(c) contacting said population with a test compound at least 1-3 days following initial culture in the differentiation medium;
(d) maintaining said population in the presence of said test compound; and
(e) assaying the population for fatty-acid uptake or accumulation, a detectable inhibition of which identifies the test compound as a potential weight loss or anti-obesity agent.

### Claim 4

A method for identifying a potential weight loss or anti-obesity agent, comprising:
(a) obtaining a high-yield, essentially pure human preadipocyte population;
(b) culturing said preadipocyte population under conditions sufficient to induce differentiation;
(c) contacting said population with a test compound at least 6-10 days following initial culture in the differentiation medium;
(d) maintaining said population in the presence of said test compound; and
(e) assaying the population for fatty-acid uptake or accumulation, a detectable inhibition of which identifies the test compound as a potential weight loss or anti-obesity agent.

### Claim 5 (depends on 1)

The method of claim 1, further comprising the step of determining the effect of the test compound on at least one of adipogenesis, lipogenesis, lipolysis, and oxidation.

### Claim 6 (depends on 3)

The method of claim 3, further comprising the step of determining the effect of the test compound on at least one of lipogenesis, lipolysis, and oxidation in the presence of said compound,wherein the effect is inhibition of lipogenesis, increase in lipolysis or increase in oxidation.

### Claim 7 (depends on 1)

The method of claim 1, wherein the conditions sufficient to induce differentiation comprise culturing said population in a serum-free differentiation medium.

### Claim 8 (depends on 1)

The method of claim 1, further comprising the steps of determining the toxicity of said test compound on said human preadipocyte population.

### Claim 9 (depends on 1)

The method of claim 1 further comprising the step of determining the toxicity of said test compound on a control cell population.

### Claim 10 (depends on 1)

A method of identifying a potential weight loss or anti-obesity agent comprising:
(a) selecting a fat modulatory compound identified according to claim 1, said compound being capable of inhibiting fatty-acid uptake or accumulation in the absence of substantial toxicity to said adipocyte population; and
(b) determining the effect of the test compound on at least one of lipogenesis, lipolysis, and oxidation in the presence of said compound,
wherein the effect is inhibition of lipogenesis, increase in lipolysis or increase in oxidation identifies said compound as a potential weight loss or anti-obesity agent.

### Claim 11 (depends on 10)

The method of claim 10, further comprising the step of determining the effect of the test compound on adipogenesis.

### Claim 12

A method for identifying a target for an agent modulating weight gain comprising:
identifying a compound that inhibits differentiation of preadipocytes to adipocytes in the absence of substantial toxicity to said preadipocytes; and determining the presence or absence of an alteration in lipogenesis, lipolysis, and oxidation in the presence of said compound, wherein an alteration signifies said target.

### Claim 13 (depends on 11)

The method of claim 11 wherein adipogenesis or differentiation of preadipocytes to adipocytes is determined by assaying for G3PD activity or PPAR γ activity.

### Claim 14 (depends on 11)

The method of claim 11 wherein adipogenesis or differentiation of preadipocytes to adipocytes is determined by assaying for expression of a gene selected from the group consisting of PPARγ, C/EBPα, C/EBPβ, aP2, and GLUT4.

### Claim 15 (depends on 10)

The method of claim 10 wherein lipogenesis is determined by measuring glucose to triglyceride conversion.

### Claim 16 (depends on 10)

The method of claim 10 wherein lipogenesis is determined by measuring oleate to triglyceride conversion.

### Claim 17 (depends on 10)

The method of claim 10 wherein lipolysis is determined by measuring release of labeled fatty acids from adipocytes.

### Claim 18 (depends on 10)

The method of claim 10 wherein lipolysis is determined by measuring glycerol release from adipocytes.

### Claim 19 (depends on 10)

The method of claim 10 wherein lipolysis is determined by measuring increased acrylodan-labeled intestinal fatty acid binding protein (ADIFAB) binding.

### Claim 20 (depends on 10)

The method of claim 10 wherein oxidation is determined by measuring oxygen consumption.

### Claim 21

A method for identifying a fat depot-specific inhibitor of human preadipocyte differentiation, comprising:
(a) identifying an inhibitor of human preadipocyte differentiation in a preadipocyte population derived from a first depot; and
(b) comparing the efficacy of said inhibitor in a preadipocyte population from a second depot, such that a fat depot-specific inhibitor of human preadipocyte differentiation is identified.

### Claim 22 (depends on 21)

The method of claim 21, wherein the first depot is subcutaneous fat depot and the second depot is an omental or mesenteric fat depot.

### Claim 23

A cell population comprising human preadipocytes, wherein said population is essentially pure.

### Claim 24 (depends on 23)

The cell population of claim 23, wherein said population is at least 95% pure.

### Claim 25 (depends on 23)

The cell population of claim 23, wherein said population is at least 98% pure.

### Claim 26 (depends on 23)

The cell population of claim 23, wherein said population is at least 99% pure.

### Claim 27 (depends on 23)

The cell population of claim 23, wherein the human preadipocytes are in suspension.

### Claim 28 (depends on 23)

The cell population of claim 23, wherein the human preadipocytes are adhered to a cell culture surface.

### Claim 29 (depends on 23)

The cell population of claim 23, wherein the human preadipocytes are of subcutaneous origin.

### Claim 30 (depends on 23)

The cell population of claim 23, wherein the human preadipocytes are of mesenteric origin.

### Claim 31 (depends on 23)

The cell population of claim 23, wherein the human preadipocytes are of omental origin.

### Claim 32

A human preadipocyte cell strain which maintains differentiative capacity over at least 8 passages.

### Claim 33 (depends on 32)

The cell strain of claim 32 which maintains differentiative capacity over at least 15 passages.

### Claim 34

A human preadipocyte cell strain which maintains differentiative capacity over at least 25 passages.

### Claim 35

A high-yield process for obtaining a human preadipocyte cell population which is essentially pure, comprising:
(a) isolating a mixed cell population from said fat tissue sample under conditions favoring a high preadipocyte yield; and
(b) removing contaminants from said mixed cell population, such that the essentially pure human preadipocyte cell population is obtained.

### Claim 36 (depends on 35)

The process of claim 35, wherein the conditions favoring a high preadipocyte yield comprise:
(a) isolation within 0 to 24 hours following harvesting of said fat tissue; and
(b) removal of undigested connective tissue from the mixed cell population utilizing gauze filters.

### Claim 37 (depends on 35)

The process of claim 35, wherein removing contaminants from said mixed cell population comprises:
(a) removing contaminating erythrocytes;
(b) removing contaminating adherent cells; and
(c) removing tissue and cellular debris.

### Claim 38 (depends on 37)

The process of claim 37, wherein removing contaminating erythrocytes is accomplished by incubating the mixed cell population in an erythrocyte lysis buffer.

### Claim 39 (depends on 37)

The process of claim 37, wherein removing contaminating adherent cells is accomplished by adhering the mixed cell population to a cell culture surface and preferentially trypsinizing the preadipocytes.

### Claim 40 (depends on 35)

The process of claim 35, wherein said fat tissue is of subcutaneous origin.

### Claim 41 (depends on 35)

The process of claim 35, wherein said fat tissue is of mesenteric origin.

### Claim 42 (depends on 40)

The process of claim 40, wherein the conditions favoring a high preadipocyte yield further include coarsely mincing said fat tissue

### Claim 43 (depends on 35)

The process of claim 35, wherein said fat tissue is of omental origin.

### Claim 44 (depends on 43)

The process of claim 43, wherein the conditions favoring a high preadipocyte yield further include:
(a) finely mincing said fat tissue; and
(b) digesting said fat tissue in the presence of a semi-artificial serum supplement or bovine serum albumin.

### Claim 45 (depends on 35)

The process of claim 35, wherein the essentially pure human preadipocyte cell population obtained is at least 85% pure.

### Claim 46 (depends on 35)

The process of claim 35, wherein the essentially pure human preadipocyte cell population obtained is at least 90% pure.

### Claim 47 (depends on 35)

The process of claim 35, wherein the essentially pure human preadipocyte cell population obtained is at least 95% pure.

### Claim 48 (depends on 35)

The process of claim 35, wherein the yield is at least 106 preadipocytes from 25 g of human fat tissue

### Claim 49 (depends on 35)

The process of claim 35, wherein the yield is at least 106 preadipocytes from 10 g of human fat tissue

### Claim 50 (depends on 35)

The process of claim 35, wherein the yield is at least 106 preadipocytes from 5 g of human fat tissue

### Claim 51 (depends on 35)

The process of claim 35, wherein the yield is at least 106 preadipocytes from 1 g of human fat tissue

### Claim 52

A method of obtaining a highly-differentiated human adipocyte cell culture, comprising:
(a) obtaining a high-yield, essentially pure population of human preadipocytes;
(b) plating said preadipocytes at a density sufficient to ensure essentially 100% confluence upon adherence to the cell culture dish or plate;
(c) maintaining said preadipocytes in a serum-free differentiation medium such that a highly-differentiated human adipocyte cell culture is obtained.

### Claim 53 (depends on 52)

The method of claim 52, wherein the cells are plated at a density of 3×104 to 5×104 cells per cm2.

### Claim 54 (depends on 52)

The method of claim 52, wherein the serum-free differentiation medium comprises a buffering component, glutamine, biotin, insulin, pantothenate, dexamethasone, triiodothyronine, rosiglitazone, fetuin, transferin, and isobutylmethylxanthine.

### Claim 55

A method of obtaining a high-yield, essentially pure culture of human preadipocytes comprising;
(a) enzymatically dissociating a mixed-cell population from human fat tissue in serum-free, bovine serum (BSA)-containing isolation media;
(b) isolating the mixed-cell population from non-cell contaminants using gauze filters;
(c) treating the mixed-cell population with an erythrocyte lysis buffer prior to plating the cell population; and
(d) selectively trypsinizing the cell population and replating in a serum-free differentiation medium at a density sufficient to insure confluence.

### Claim 56 (depends on 55)

A method of obtaining a highly-differentiated human adipocyte culture comprising obtaining a high-yield, essentially pure culture of human preadipocytes according to the method of claim 55 and further maintaining the culture in the serum-free differentiation medium such that a highly-differentiated human adipocyte cell culture is obtained.
